Convergence considers IPO after GSK spin-off, as European biotech revives-Reuters
Convergence Pharmaceuticals, a specialist pain drug company spun off from GlaxoSmithKline, is preparing for a possible stock market listing as British biotech companies enjoy a revival of interest from investors, Reuters reported.
16 June 2014•3 mins read
